Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer.

Raz Y, Cohen N, Shani O, Bell RE, Novitskiy SV, Abramovitz L, Levy C, Milyavsky M, Leider-Trejo L, Moses HL, Grisaru D, Erez N.

J Exp Med. 2018 Dec 3;215(12):3075-3093. doi: 10.1084/jem.20180818. Epub 2018 Nov 23.

PMID:
30470719
2.

Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.

Pickup MW, Owens P, Gorska AE, Chytil A, Ye F, Shi C, Weaver VM, Kalluri R, Moses HL, Novitskiy SV.

Cancer Immunol Res. 2017 Sep;5(9):718-729. doi: 10.1158/2326-6066.CIR-16-0311. Epub 2017 Aug 3.

3.

Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor.

Polosukhina D, Love HD, Moses HL, Lee E, Zent R, Clark PE.

Oncol Res. 2017 Nov 2;25(9):1653-1664. doi: 10.3727/096504017X14992942781895. Epub 2017 Jul 10.

4.

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL.

J Clin Invest. 2017 Mar 1;127(3):1116. doi: 10.1172/JCI93333. Epub 2017 Mar 1. No abstract available.

5.

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN 3rd, Zent R, Clark PE.

Mol Oncol. 2017 Apr;11(4):405-421. doi: 10.1002/1878-0261.12044. Epub 2017 Mar 15.

6.

TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.

Pickup MW, Owens P, Moses HL.

Cold Spring Harb Perspect Biol. 2017 May 1;9(5). pii: a022285. doi: 10.1101/cshperspect.a022285. Review.

PMID:
28062564
7.

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A.

Clin Cancer Res. 2017 Jul 1;23(13):3371-3384. doi: 10.1158/1078-0432.CCR-16-2142. Epub 2016 Dec 21. Erratum in: Clin Cancer Res. 2018 Aug 1;24(15):3782.

8.

TβRIII Expression in Human Breast Cancer Stroma and the Role of Soluble TβRIII in Breast Cancer Associated Fibroblasts.

Jovanović B, Pickup MW, Chytil A, Gorska AE, Johnson KC, Moses HL, Owens P.

Cancers (Basel). 2016 Nov 4;8(11). pii: E100.

9.

Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine.

Lyman GH, Moses HL.

N Engl J Med. 2016 Jul 7;375(1):4-6. doi: 10.1056/NEJMp1604033. Epub 2016 Jun 1. No abstract available.

PMID:
27353537
10.

The Discovery and Early Days of TGF-β: A Historical Perspective.

Moses HL, Roberts AB, Derynck R.

Cold Spring Harb Perspect Biol. 2016 Jul 1;8(7). pii: a021865. doi: 10.1101/cshperspect.a021865. Review.

11.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

12.

Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM.

Nat Med. 2016 May;22(5):497-505. doi: 10.1038/nm.4082. Epub 2016 Apr 18.

13.

Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream.

Lyman GH, Moses HL.

J Clin Oncol. 2016 Jun 10;34(17):2061-6. doi: 10.1200/JCO.2016.67.3160. Epub 2016 Apr 11.

PMID:
27069080
14.

The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model.

Ampuja M, Alarmo EL, Owens P, Havunen R, Gorska AE, Moses HL, Kallioniemi A.

Cancer Lett. 2016 Jun 1;375(2):238-244. doi: 10.1016/j.canlet.2016.03.008. Epub 2016 Mar 9.

PMID:
26970275
15.

Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.

Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, Moses HL, Franco AT.

Cancer Res. 2016 Apr 1;76(7):1804-13. doi: 10.1158/0008-5472.CAN-15-2351. Epub 2016 Jan 27.

16.

Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.

Hover LD, Owens P, Munden AL, Wang J, Chambless LB, Hopkins CR, Hong CC, Moses HL, Abel TW.

Neuro Oncol. 2016 Jul;18(7):928-38. doi: 10.1093/neuonc/nov310. Epub 2015 Dec 18.

17.

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R.

Cancer Cell. 2015 Dec 14;28(6):831-833. doi: 10.1016/j.ccell.2015.11.002. Epub 2015 Dec 14. No abstract available.

18.

Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.

Pickup MW, Hover LD, Guo Y, Gorska AE, Chytil A, Novitskiy SV, Moses HL, Owens P.

Oncotarget. 2015 Sep 8;6(26):22890-904.

19.

Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.

Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.

20.

Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P.

Cancer Lett. 2015 Nov 1;368(1):79-87. doi: 10.1016/j.canlet.2015.07.032. Epub 2015 Jul 30.

21.

A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.

Yi Y, Polosukhina D, Love HD, Hembd A, Pickup M, Moses HL, Lovvorn HN 3rd, Zent R, Clark PE.

J Urol. 2015 Dec;194(6):1762-70. doi: 10.1016/j.juro.2015.04.090. Epub 2015 Apr 29.

22.

TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.

Shaw AK, Pickup MW, Chytil A, Aakre M, Owens P, Moses HL, Novitskiy SV.

PLoS One. 2015 Jan 28;10(1):e0117908. doi: 10.1371/journal.pone.0117908. eCollection 2015.

23.

Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells.

Huh SJ, Clement K, Jee D, Merlini A, Choudhury S, Maruyama R, Yoo R, Chytil A, Boyle P, Ran FA, Moses HL, Barcellos-Hoff MH, Jackson-Grusby L, Meissner A, Polyak K.

Stem Cell Reports. 2015 Feb 10;4(2):297-311. doi: 10.1016/j.stemcr.2014.12.009. Epub 2015 Jan 22.

24.

Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.

Novitskiy SV, Forrester E, Pickup MW, Gorska AE, Chytil A, Aakre M, Polosukhina D, Owens P, Yusupova DR, Zhao Z, Ye F, Shyr Y, Moses HL.

Breast Cancer Res. 2014 Oct 4;16(5):425. doi: 10.1186/s13058-014-0425-7.

25.

Concerted loss of TGFβ-mediated proliferation control and E-cadherin disrupts epithelial homeostasis and causes oral squamous cell carcinoma.

Andl T, Le Bras GF, Richards NF, Allison GL, Loomans HA, Washington MK, Revetta F, Lee RK, Taylor C, Moses HL, Andl CD.

Carcinogenesis. 2014 Nov;35(11):2602-10. doi: 10.1093/carcin/bgu194. Epub 2014 Sep 18.

26.

BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.

Pickup MW, Hover LD, Polikowsky ER, Chytil A, Gorska AE, Novitskiy SV, Moses HL, Owens P.

Mol Oncol. 2015 Jan;9(1):179-91. doi: 10.1016/j.molonc.2014.08.004. Epub 2014 Aug 23.

27.

Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.

Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P, Feoktistov I, Moses HL, Novitskiy SV.

J Immunol. 2014 Sep 15;193(6):3155-64. doi: 10.4049/jimmunol.1400578. Epub 2014 Aug 15.

28.

Inhibition of BMP signaling suppresses metastasis in mammary cancer.

Owens P, Pickup MW, Novitskiy SV, Giltnane JM, Gorska AE, Hopkins CR, Hong CC, Moses HL.

Oncogene. 2015 May 7;34(19):2437-49. doi: 10.1038/onc.2014.189. Epub 2014 Jul 7.

29.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

30.

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R.

Cancer Cell. 2014 Jun 16;25(6):719-34. doi: 10.1016/j.ccr.2014.04.005. Epub 2014 May 22. Erratum in: Cancer Cell. 2015 Dec 14;28(6):831-3.

31.

ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.

Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A.

Cancer Res. 2014 Mar 1;74(5):1404-15. doi: 10.1158/0008-5472.CAN-13-1296. Epub 2014 Jan 2.

32.

The roles of TGFβ in the tumour microenvironment.

Pickup M, Novitskiy S, Moses HL.

Nat Rev Cancer. 2013 Nov;13(11):788-99. doi: 10.1038/nrc3603. Epub 2013 Oct 17. Review.

33.

Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.

Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL.

Cancer Res. 2013 Sep 1;73(17):5336-46. doi: 10.1158/0008-5472.CAN-13-0012. Epub 2013 Jul 15.

34.

Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion.

Owens P, Polikowsky H, Pickup MW, Gorska AE, Jovanovic B, Shaw AK, Novitskiy SV, Hong CC, Moses HL.

PLoS One. 2013 Jun 28;8(6):e67533. doi: 10.1371/journal.pone.0067533. Print 2013.

35.

Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.

Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, Ikenoue T, Tateishi K, Nakai Y, Isayama H, Morishita Y, Omata M, Moses HL, Koike K.

Cancer Res. 2013 Apr 1;73(7):2221-34. doi: 10.1158/0008-5472.CAN-12-1453. Epub 2013 Feb 1.

36.

Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.

Takahashi R, Hirata Y, Sakitani K, Nakata W, Kinoshita H, Hayakawa Y, Nakagawa H, Sakamoto K, Hikiba Y, Ijichi H, Moses HL, Maeda S, Koike K.

Cancer Sci. 2013 Mar;104(3):337-44. doi: 10.1111/cas.12080. Epub 2013 Jan 24.

37.

Turn off the IDO: will clinical trials be successful?

Novitskiy SV, Moses HL.

Cancer Discov. 2012 Aug;2(8):673-5. doi: 10.1158/2159-8290.CD-12-0311.

38.

Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.

Matise LA, Palmer TD, Ashby WJ, Nashabi A, Chytil A, Aakre M, Pickup MW, Gorska AE, Zijlstra A, Moses HL.

Breast Cancer Res. 2012 Jul 2;14(4):R98. doi: 10.1186/bcr3217.

39.

Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties.

Novitskiy SV, Pickup MW, Chytil A, Polosukhina D, Owens P, Moses HL.

J Leukoc Biol. 2012 Sep;92(3):641-51. doi: 10.1189/jlb.1211639. Epub 2012 Jun 8.

40.

Pathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among Asians.

Ma X, Beeghly-Fadiel A, Lu W, Shi J, Xiang YB, Cai Q, Shen H, Shen CY, Ren Z, Matsuo K, Khoo US, Iwasaki M, Long J, Zhang B, Ji BT, Zheng Y, Wang W, Hu Z, Liu Y, Wu PE, Shieh YL, Wang S, Xie X, Ito H, Kasuga Y, Chan KY, Iwata H, Tsugane S, Gao YT, Shu XO, Moses HL, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1176-84. doi: 10.1158/1055-9965.EPI-12-0118. Epub 2012 Apr 26.

41.

p120-catenin is essential for terminal end bud function and mammary morphogenesis.

Kurley SJ, Bierie B, Carnahan RH, Lobdell NA, Davis MA, Hofmann I, Moses HL, Muller WJ, Reynolds AB.

Development. 2012 May;139(10):1754-64. doi: 10.1242/dev.072769. Epub 2012 Mar 29.

42.

TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.

Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, Shyr Y, Moses HL.

Cancer Discov. 2011 Oct;1(5):430-41. doi: 10.1158/2159-8290.CD-11-0100.

43.

β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R.

Am J Pathol. 2011 Dec;179(6):3045-55. doi: 10.1016/j.ajpath.2011.08.006. Epub 2011 Oct 8.

44.

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL.

J Clin Invest. 2011 Oct;121(10):4106-17. doi: 10.1172/JCI42754. Epub 2011 Sep 19.

45.

Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts.

Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC, Moses HL, Shyr CR, Chang C, Yeh S.

Prostate. 2012 Mar;72(4):437-49. doi: 10.1002/pros.21445. Epub 2011 Jul 7.

46.

Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.

Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, West J, Moses HL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2814-9. doi: 10.1073/pnas.1101139108. Epub 2011 May 16.

47.

Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.

Fang WB, Jokar I, Chytil A, Moses HL, Abel T, Cheng N.

Clin Exp Metastasis. 2011 Apr;28(4):351-66. doi: 10.1007/s10585-011-9373-0. Epub 2011 Mar 4.

48.

Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

M'Koma AE, Moses HL, Adunyah SE.

Int J Colorectal Dis. 2011 May;26(5):533-52. doi: 10.1007/s00384-011-1137-4. Epub 2011 Feb 11. Review.

49.

Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas.

Johnson MD, Shaw AK, O'Connell MJ, Sim FJ, Moses HL.

J Neurooncol. 2011 Jun;103(2):277-85. doi: 10.1007/s11060-010-0399-y. Epub 2010 Sep 19.

PMID:
20853018
50.

TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis.

Clark PE, Polosukhina DA, Gyabaah K, Moses HL, Thorburn A, Zent R.

J Urol. 2010 Sep;184(3):1166-74. doi: 10.1016/j.juro.2010.04.064. Epub 2010 Jul 21.

Supplemental Content

Loading ...
Support Center